Treatment News

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News


April 30, 2013
FDA Rejects Elvitegravir and Cobicistat as Individual Meds
The FDA has rejected Gilead Sciences’ application for approval of the HIV antiretrovirals elvitegravir and cobicistat for use as stand-alone drugs.
April 29, 2013
Another HIV Vaccine Trial Shuts Down
Researchers shuttered a trial after the experimental vaccine failed to both prevent HIV transmission and to reduce viral load in those contracting the virus.
Sofosbuvir, Daclatasvir Combo Cures 100% in Hep C Trial
Sofosbuvir and daclatasvir, taken with or without ribavirin, cured 100 percent of previously treated participants of hepatitis C virus in a recent trial.
April 26, 2013
Cord Blood Transplant May Cure Boy With Leukemia of HIV
Physicians at the University of Minnesota have performed the first-ever attempt to cure a boy of HIV through a cord blood transplant to treat his leukemia.
April 25, 2013
HIV Therapy May Protect Heart Function in Children and Teens
Antiretroviral therapy among HIV-positive children and teens appears unassociated with impaired heart function; it may actually protect against heart disease.
April 24, 2013
Viral Load Persists in Genital Tracts of More Women Than Men Taking ARVs
About 16 percent of women and 4 percent of men taking HIV therapy in a recent study experienced a persistent viral load in their genital secretions.
April 22, 2013
FDA Updates Atripla Label
The U.S. Food and Drug Administration (FDA) has made changes to the label for the single-pill HIV antiretroviral combination therapy Atripla.
Insight on Protein That Blocks HIV Replication May Help Battle Viral Reservoir
Researchers have discovered the regulation process for a protein that prevents HIV from making copies of itself in white blood cells.
April 19, 2013
Hep C Transmission Among Gay Men Dates Back Decades; HIV a Major Risk Factor
Hepatitis C has transmitted among gay men since at least the early 1980s, with HIV-positive men at much higher risk, particularly those with lower CD4 counts.
April 18, 2013
More Study Needed Linking Microbes, Circumcision to HIV Risk
Circumcision lowers the population of microbes on the penis, which may partially explain how the surgery helps reduce the risk of heterosexual HIV transmission.
April 17, 2013
Study Suggests PrEP May Not Increase Overall Sexual Risk-Taking in Gay Men
Pre-exposure prophylaxis (PrEP) to prevent HIV infection does not appear to increase overall sexual risk-taking among HIV-negative gay men.
April 15, 2013
Viread and Epivir Lower Risk of Hepatitis B Infection in HIV-Positive Gay Men
Viread (tenofovir) and Epivir (lamivudine) lower the risk of infection with hepatitis B among HIV-positive gay men who haven’t been vaccinated against hep B.
April 12, 2013
HPV Vaccine May Leave HIV-Positive Women Vulnerable to High-Risk Strains
The current HPV vaccines do not protect against high-risk strains that immune-compromised women, including those with uncontrolled HIV, may acquire. 
April 11, 2013
Researchers Hoping to Replicate Case of Functionally Cured Child
A group of scientists is laying the groundwork for an attempt to replicate the case of the child who was apparently functionally cured of HIV.
April 10, 2013
Irregular Heartbeat Risk Tied to Advanced HIV
More advanced HIV disease is associated with an increased risk of atrial fibrillation, the most common form of irregular heartbeat (cardiac arrhythmia).
April 09, 2013
Reformulated Vaginal Microbicide Gel Looks Promising for Rectal Use
A reformulated vaginal microbicide gel has proved safe and well tolerated in HIV-negative women and men using it rectally.
April 08, 2013
Well-Controlled HIV and High CD4s Can Reduce Risk of Cervical HPV Infection
A suppressed viral load and a high CD4 count are associated with a reduced risk of persistent cervical human papillomavirus (HPV).
April 05, 2013
HIV-Positive Thai Gay Men at High Risk for Precancerous Anal Lesions
Gay men with HIV in a Thai study had three times the risk of developing high-grade precancerous anal lesions, a precursor to anal cancer.
April 04, 2013
Findings on 'Broadly Neutralizing Antibodies' May Be Key to HIV Vaccine
For the first time, scientists have mapped the coevolution of HIV and the corresponding immune response, providing clues for vaccine development.
April 03, 2013
Why HIV That Transmits Is More Infectious and Resilient
HIV that transmits successfully is particularly resistant to the human immune response and is also structured to better access and enter immune cells
April 02, 2013
FDA Approves a First-in-Class Diabetes Drug: Invokana
The FDA has approved the first in a new class of medications to treat type 2 diabetes, provided the drug manufacturer conducts additional research.
April 01, 2013
Many People on Therapy for HIV Should Qualify for Life Insurance
Many people with HIV on successful treatment have a low enough mortality risk to qualify for life insurance.
More Treatment News

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ



Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    CuteBoyinQns
    Jackson Heights
    New York


    romanticseattle
    Tacoma
    Washington


    pevans
    San Francisco
    California


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.